Glyco Property List
Pooled literature properties (glycanDB). Optional filters: ?dataset=uv_vis&property_key=...
GET /api/gdd/glyco-properties/?format=api&page=37
{ "count": 839, "next": "http://glycodata.org/api/gdd/glyco-properties/?format=api&page=38", "previous": "http://glycodata.org/api/gdd/glyco-properties/?format=api&page=36", "results": [ { "id": 721, "dataset": "heparin", "entity": "heparin (UFH)", "entity_group": "", "entity_class": "heparin (UFH)", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "1", "unit": "ratio", "value_reported": "1.0", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa to anti-IIa ratio of UFH (by definition ~1:1)", "conditions": "anti-Xa to anti-IIa ratio of UFH (by definition ~1:1)", "conditions_detail": "anti-Xa to anti-IIa ratio of UFH (by definition ~1:1)", "doi": "10.1093/eurheartj/ehl492", "source_url": "https://doi.org/10.1093/eurheartj/ehl492", "year": "2007", "confidence": "high", "comments": "\"In contrast, by definition, UFH has an anti-Xa to anti-IIa ratio of 1\" — European Heart Journal review [De Caterina R, Husted S, Wallentin L, et al., 2007, confidence: high]" }, { "id": 722, "dataset": "heparin", "entity": "LMWH (class)", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "4.75", "unit": "kDa", "value_reported": "4000-5500", "unit_reported": "Da", "method": "Review", "method_detail": "mean molecular weight of LMWH class (range 2,000-9,000 Da, mean depends on product)", "conditions": "mean molecular weight of LMWH class (range 2,000-9,000 Da, mean depends on product)", "conditions_detail": "mean molecular weight of LMWH class (range 2,000-9,000 Da, mean depends on product) | range Da: 2000-9000", "doi": "10.1186/1477-9560-9-5", "source_url": "https://doi.org/10.1186/1477-9560-9-5", "year": "2011", "confidence": "high", "comments": "\"Each LMWH consists of a heterogeneous mixture of polysaccharide chains with molecular weights ranging from 2,000 to 9,000 Da (mean 4,000-5,500 Da, depending on the LMWH).\" [Fareed J, Adiguzel C, Thethi I, 2011, confidence: high]" }, { "id": 723, "dataset": "heparin", "entity": "LMWH (class)", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa activity", "property_key": "anti_xa_activity", "value": "100", "unit": "IU/mg", "value_reported": "100", "unit_reported": "IU/mg", "method": "Review", "method_detail": "approximate specific anti-Xa activity of LMWHs (vs ~700 for fondaparinux)", "conditions": "approximate specific anti-Xa activity of LMWHs (vs ~700 for fondaparinux)", "conditions_detail": "approximate specific anti-Xa activity of LMWHs (vs ~700 for fondaparinux)", "doi": "10.1093/eurheartj/ehl492", "source_url": "https://doi.org/10.1093/eurheartj/ehl492", "year": "2007", "confidence": "high", "comments": "\"The specific anti-Xa activity of fondaparinux is about seven-fold higher than that of LMWHs (about 700 anti-Xa U/ mg and 100 anti-Xa U/mg, respectively).\" — U/mg = IU/mg [De Caterina R, Husted S, Wallentin L, et al., 2007, confidence: high]" }, { "id": 724, "dataset": "heparin", "entity": "LMWH (class)", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "3", "unit": "ratio", "value_reported": "2.0-4.0", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa to anti-IIa ratio range for LMWHs", "conditions": "anti-Xa to anti-IIa ratio range for LMWHs", "conditions_detail": "anti-Xa to anti-IIa ratio range for LMWHs", "doi": "10.1093/eurheartj/ehl492", "source_url": "https://doi.org/10.1093/eurheartj/ehl492", "year": "2007", "confidence": "high", "comments": "\"Consequently, LMWH preparations have greater capacity to promote FXa inhibition than thrombin inhibition and have anti-Xa to anti-IIa ratios that range from 2:1 to 4:1 depending on their molecular weight profiles.\" [De Caterina R, Husted S, Wallentin L, et al., 2007, confidence: high]" }, { "id": 725, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "4.5", "unit": "kDa", "value_reported": "4.5", "unit_reported": "kDa", "method": "Review", "method_detail": "mean molecular weight (4500 daltons)", "conditions": "mean molecular weight (4500 daltons)", "conditions_detail": "mean molecular weight (4500 daltons)", "doi": "10.1136/ejhpharm-2020-002262", "source_url": "https://doi.org/10.1136/ejhpharm-2020-002262", "year": "2020", "confidence": "high", "comments": "\"LMWH with lower mean molecular weights (enoxaparin 4500 daltons, bemiparin 3600 daltons).\" [Diaz Gomez E, Suarez del Olmo D, Corregidor Luna L, et al., 2020, confidence: high]" }, { "id": 726, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "4.5", "unit": "kDa", "value_reported": "3500-5500", "unit_reported": "Da", "method": "Review", "method_detail": "average molecular weight of enoxaparin (benzylation + alkaline depolymerization)", "conditions": "average molecular weight of enoxaparin (benzylation + alkaline depolymerization)", "conditions_detail": "average molecular weight of enoxaparin (benzylation + alkaline depolymerization)", "doi": "10.1186/s12893-024-02440-0", "source_url": "https://doi.org/10.1186/s12893-024-02440-0", "year": "2024", "confidence": "high", "comments": "\"Enoxaparin is derived from UFH by benzylation followed by alkaline depolymerization, has an average molecular weight of 3500-5500Da, and contains 10,000 International Unit (IU) of anti-Xa factor (AxaIU, WHO compendial units) per ml\" — BMC Surgery [Gao X, Jin X, Huang R, et al., 2024, confidence: high]" }, { "id": 727, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "3.9", "unit": "ratio", "value_reported": "3.9", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa/anti-IIa activity ratio", "conditions": "anti-Xa/anti-IIa activity ratio", "conditions_detail": "anti-Xa/anti-IIa activity ratio", "doi": "10.1177/1076029617729215", "source_url": "https://doi.org/10.1177/1076029617729215", "year": "2017", "confidence": "high", "comments": "\"it has the lowest (2:1) anti-Xa/anti-IIa activity ratio, compared to bemiparin’s ratio of 8:1 and enoxaparin’s ratio of 3.9:1.\" [Dimakakos E, Vathiotis I, Syrigos K, 2017, confidence: high]" }, { "id": 728, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "3.7", "unit": "ratio", "value_reported": "3.7", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa : anti-IIa ratio (3.7:1)", "conditions": "anti-Xa : anti-IIa ratio (3.7:1)", "conditions_detail": "anti-Xa : anti-IIa ratio (3.7:1)", "doi": "10.4212/cjhp.v68i1.1423", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4350497/", "year": "2015", "confidence": "medium", "comments": "\"Enoxaparin ... 3.7 : 1\" — value from comparative ratio table [Egan G, Ensom MHH, 2015, confidence: medium]" }, { "id": 729, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "3.2", "unit": "ratio", "value_reported": "3.2", "unit_reported": "ratio", "method": "Experiment", "method_detail": "anti-Xa/anti-IIa ratio of enoxaparin used in hip-surgery prophylaxis trial", "conditions": "anti-Xa/anti-IIa ratio of enoxaparin used in hip-surgery prophylaxis trial", "conditions_detail": "anti-Xa/anti-IIa ratio of enoxaparin used in hip-surgery prophylaxis trial", "doi": "10.1046/j.1365-2141.1999.01153.x", "source_url": "https://doi.org/10.1046/j.1365-2141.1999.01153.x", "year": "1999", "confidence": "high", "comments": "\"The anti-Xa/anti-IIa ratio of tinzaparin is 1.7 and that of enoxaparin is 3.2.\" — same paper also states enoxaparin ratio ~3.3 [Bara L, Planes A, Samama MM, 1999, confidence: high]" }, { "id": 730, "dataset": "heparin", "entity": "enoxaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa activity", "property_key": "anti_xa_activity", "value": "100", "unit": "IU/mg", "value_reported": "100", "unit_reported": "IU/mg", "method": "Review", "method_detail": "specific anti-Xa activity (1 mg enoxaparin = 100 anti-Xa units)", "conditions": "specific anti-Xa activity (1 mg enoxaparin = 100 anti-Xa units)", "conditions_detail": "specific anti-Xa activity (1 mg enoxaparin = 100 anti-Xa units)", "doi": "10.1093/eurheartj/ehl492", "source_url": "https://doi.org/10.1093/eurheartj/ehl492", "year": "2007", "confidence": "medium", "comments": "\"In such cases, 1 mg neutralizes 100 anti-Xa units of LMWHs.\" — Standard clinical conversion: enoxaparin ~100 anti-Xa IU/mg; applies to LMWHs generally [De Caterina R, Husted S, Wallentin L, et al., 2007, confidence: medium]" }, { "id": 731, "dataset": "heparin", "entity": "dalteparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "5", "unit": "kDa", "value_reported": "5.0", "unit_reported": "kDa", "method": "Review", "method_detail": "mean molecular weight (5000 daltons)", "conditions": "mean molecular weight (5000 daltons)", "conditions_detail": "mean molecular weight (5000 daltons)", "doi": "10.1136/ejhpharm-2020-002262", "source_url": "https://doi.org/10.1136/ejhpharm-2020-002262", "year": "2020", "confidence": "high", "comments": "\"tinzaparin (mean molecular weight 6500 daltons) and dalteparin (5000 daltons)\" [Diaz Gomez E, Suarez del Olmo D, Corregidor Luna L, et al., 2020, confidence: high]" }, { "id": 732, "dataset": "heparin", "entity": "dalteparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "5.7", "unit": "kDa", "value_reported": "5.7", "unit_reported": "kDa", "method": "Review", "method_detail": "molecular weight cited as 5700 Da (alternate value)", "conditions": "molecular weight cited as 5700 Da (alternate value)", "conditions_detail": "molecular weight cited as 5700 Da (alternate value)", "doi": "10.1177/1076029617729215", "source_url": "https://doi.org/10.1177/1076029617729215", "year": "2017", "confidence": "high", "comments": "\"tinzaparin (6500 Da) and to a lesser extent dalteparin (5700 Da) employ first-order pharmacokinetics\" — Second reported dalteparin MW; values vary 5000-5700 Da across sources [Dimakakos E, Vathiotis I, Syrigos K, 2017, confidence: high]" }, { "id": 733, "dataset": "heparin", "entity": "dalteparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "2.8", "unit": "ratio", "value_reported": "2.8", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa : anti-IIa ratio (2.8:1)", "conditions": "anti-Xa : anti-IIa ratio (2.8:1)", "conditions_detail": "anti-Xa : anti-IIa ratio (2.8:1)", "doi": "10.4212/cjhp.v68i1.1423", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4350497/", "year": "2015", "confidence": "medium", "comments": "\"Dalteparin ... 2.8 : 1\" — from comparative ratio table [Egan G, Ensom MHH, 2015, confidence: medium]" }, { "id": 734, "dataset": "heparin", "entity": "tinzaparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "6.5", "unit": "kDa", "value_reported": "6.5", "unit_reported": "kDa", "method": "Review", "method_detail": "average molecular mass 6500 Da (range 5500-7500 Da); produced by heparinase depolymerization of porcine UFH", "conditions": "average molecular mass 6500 Da (range 5500-7500 Da); produced by heparinase depolymerization of porcine UFH", "conditions_detail": "average molecular mass 6500 Da (range 5500-7500 Da); produced by heparinase depolymerization of porcine UFH | range Da: 5500-7500", "doi": "10.1177/1076029617729215", "source_url": "https://doi.org/10.1177/1076029617729215", "year": "2017", "confidence": "high", "comments": "\"The enzymatic depolymerization of UFH from porcine intestinal mucosa via the utilization of Flavobacterium heparinum heparinase produces tinzaparin sodium (Innohep), a LMWH with an average molecular mass of 6500 Da (varying from 5500 to 7500 Da).\" — Highest mean MW among LMWHs [Dimakakos E, Vathiotis I, Syrigos K, 2017, confidence: high]" }, { "id": 735, "dataset": "heparin", "entity": "tinzaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "2", "unit": "ratio", "value_reported": "2.0", "unit_reported": "ratio", "method": "Review", "method_detail": "lowest anti-Xa/anti-IIa ratio among LMWHs (2:1)", "conditions": "lowest anti-Xa/anti-IIa ratio among LMWHs (2:1)", "conditions_detail": "lowest anti-Xa/anti-IIa ratio among LMWHs (2:1)", "doi": "10.1177/1076029617729215", "source_url": "https://doi.org/10.1177/1076029617729215", "year": "2017", "confidence": "high", "comments": "\"Thus, it has the lowest (2:1) anti-Xa/anti-IIa activity ratio, compared to bemiparin’s ratio of 8:1 and enoxaparin’s ratio of 3.9:1.\" [Dimakakos E, Vathiotis I, Syrigos K, 2017, confidence: high]" }, { "id": 736, "dataset": "heparin", "entity": "tinzaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "1.7", "unit": "ratio", "value_reported": "1.7", "unit_reported": "ratio", "method": "Experiment", "method_detail": "anti-Xa/anti-IIa ratio of tinzaparin (1.7; stated <2)", "conditions": "anti-Xa/anti-IIa ratio of tinzaparin (1.7; stated <2)", "conditions_detail": "anti-Xa/anti-IIa ratio of tinzaparin (1.7; stated <2)", "doi": "10.1046/j.1365-2141.1999.01153.x", "source_url": "https://doi.org/10.1046/j.1365-2141.1999.01153.x", "year": "1999", "confidence": "high", "comments": "\"The anti-Xa/anti-IIa ratio of tinzaparin is 1.7 and that of enoxaparin is 3.2.\" — consistent with ratio <2 reported in same paper [Bara L, Planes A, Samama MM, 1999, confidence: high]" }, { "id": 737, "dataset": "heparin", "entity": "tinzaparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "6", "unit": "ratio", "value_reported": "6.0", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa : anti-IIa ratio reported as 6:1 (note: conflicts with other reviews reporting ~2:1)", "conditions": "anti-Xa : anti-IIa ratio reported as 6:1 (note: conflicts with other reviews reporting ~2:1)", "conditions_detail": "anti-Xa : anti-IIa ratio reported as 6:1 (note: conflicts with other reviews reporting ~2:1)", "doi": "10.4212/cjhp.v68i1.1423", "source_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4350497/", "year": "2015", "confidence": "low", "comments": "\"Tinzaparin ... 6 : 1\" — Outlier; most sources give tinzaparin the lowest ratio (~1.7-2.0). Flagged for discrepancy. [Egan G, Ensom MHH, 2015, confidence: low]" }, { "id": 738, "dataset": "heparin", "entity": "nadroparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "4.3", "unit": "kDa", "value_reported": "3600-5000", "unit_reported": "Da", "method": "Review", "method_detail": "average molecular weight (nitrous acid depolymerization)", "conditions": "average molecular weight (nitrous acid depolymerization)", "conditions_detail": "average molecular weight (nitrous acid depolymerization)", "doi": "10.1186/s12893-024-02440-0", "source_url": "https://doi.org/10.1186/s12893-024-02440-0", "year": "2024", "confidence": "high", "comments": "\"Nadroparin is derived from UFH by nitrous acid depolymerization, has an average molecular weight of 3600-5000Da, and contains 10,250 AxaIU per ml\" [Gao X, Jin X, Huang R, et al., 2024, confidence: high]" }, { "id": 739, "dataset": "heparin", "entity": "bemiparin", "entity_group": "", "entity_class": "LMWH", "property": "molecular weight", "property_key": "molecular_weight", "value": "3.6", "unit": "kDa", "value_reported": "3.6", "unit_reported": "kDa", "method": "Review", "method_detail": "molecular weight 3600 daltons (second-generation LMWH)", "conditions": "molecular weight 3600 daltons (second-generation LMWH)", "conditions_detail": "molecular weight 3600 daltons (second-generation LMWH)", "doi": "10.1159/000073608", "source_url": "https://doi.org/10.1159/000073608", "year": "2002", "confidence": "high", "comments": "\"Bemiparin, a new second generation LMWH, with a molecular weight of 3600 daltons and an anti-Xa/anti-IIa ratio greater than 8\" [Harenberg J, 2002, confidence: high]" }, { "id": 740, "dataset": "heparin", "entity": "bemiparin", "entity_group": "", "entity_class": "LMWH", "property": "anti-Xa/IIa ratio", "property_key": "anti_xa_iia_ratio", "value": "8", "unit": "ratio", "value_reported": "8.0", "unit_reported": "ratio", "method": "Review", "method_detail": "anti-Xa/anti-IIa ratio (8:1; highest among LMWHs)", "conditions": "anti-Xa/anti-IIa ratio (8:1; highest among LMWHs)", "conditions_detail": "anti-Xa/anti-IIa ratio (8:1; highest among LMWHs)", "doi": "10.1177/1076029617729215", "source_url": "https://doi.org/10.1177/1076029617729215", "year": "2017", "confidence": "high", "comments": "\"compared to bemiparin’s ratio of 8:1 and enoxaparin’s ratio of 3.9:1.\" — Harenberg 2002 corroborates: ratio >8 [Dimakakos E, Vathiotis I, Syrigos K, 2017, confidence: high]" } ] }